FDA grants priority review to TAR-200, which demonstrated an 82% complete response in high-risk bladder cancer unresponsive ...

Johnson & Johnson (J&J) has announced that its investigational intravesical gemcitabine releasing system has been accepted ...

Raritan, New Jersey Friday, July 18, 2025, 15:00 Hrs [IST] ...

Bladder cancer symptoms often go unnoticed until it's too late. Learn the warning signs most people ignore and how early ...

A New Jersey father is facing a devastating diagnosis, just months after his wife died of the same.Jeff Krajicek, of Sparta, ...

Johnson & Johnson (NYSE:JNJ) announced on Thursday that the U.S. FDA granted priority review for its new drug application aimed at getting marketing approval for TAR-200, a drug-releasing system for ...

Bladder cancer is seen as a condition that gives off loud warning bells, blood in urine, painful urination, and sudden weight ...

The New Brunswick, N.J., pharmaceutical giant on Thursday said the application covers TAR-200 for the treatment of patients with Bacillus Calmette-Guerin-unresponsive high-risk non-muscle invasive ...

Chemotherapy used to target and kill bladder cancer cells may trigger an inflammatory response that ultimately may make the ...

Beat bladder cancer with early detection! Expert insights reveal how a multidisciplinary approach can improve treatment ...

Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) granted Priority Review to the ...

Priority review was based on results from the Phase IIb SunRISe-1 trial, which showed that patients treated with TAR-200 for ...